Research
Hormonal
Liraglutide reduced global eating disorder risk scores.
Practitioners may consider liraglutide as a treatment option for reducing eating disorder risk in patients with obesity or Type 2 diabetes.
StrongSupportsmedium confidence
Liraglutide reduced global eating disorder risk scores, with no differences between groups (k = 1).
Why this rating
Based on the inclusion of multiple studies and the synthesis of data.
Source
GLP‐1 Receptor Agonist Medications for Obesity and Type 2 Diabetes Treatment: A Rapid Review of Changes in Eating Behaviors and Eating Disorder Risk
Hiba Jebeile et al. · Obesity Reviews · 2025
DOI 10.1111/obr.70049
review · n=8997Cited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →